CIK 0001674416
- Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Operating
- EIN
- 473173478
- Phone
- +1 617-315-4600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-06-08 | Novak Rodger Chief Executive Officer | Sale | −4,203 | $15.00 | $63K | 1,215,005 |
| 2017-06-08 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −4,203 | 110,240 | ||
| 2017-05-31 | Behbahani Ali Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2017-05-31 | George Simeon Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2017-05-31 | EMSTER KURT VON Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2017-05-31 | CAGNONI PABLO J Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2017-05-31 | Woiwode Thomas Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2017-05-31 | Bolzon Bradley J PhD Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2017-05-31 | KASINGER JAMES R. General Counsel and Secretary | Grant or award · Stock Options (Right to Buy) | +123,000 | 123,000 | ||
| 2017-05-31 | COLES N ANTHONY Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2017-05-30 | Novak Rodger Chief Executive Officer | Exercise or conversion | +3,650 | $1.81 | $7K | 1,218,655 |
| 2017-05-30 | Novak Rodger Chief Executive Officer | Sale | −3,650 | $15.02 | $55K | 1,215,005 |
| 2017-05-30 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −3,650 | 114,443 | ||
| 2017-05-17 | Novak Rodger Chief Executive Officer | Exercise or conversion | +25,923 | $1.81 | $47K | 1,240,928 |
| 2017-05-17 | Novak Rodger Chief Executive Officer | Sale | −25,923 | $16.03 | $416K | 1,215,005 |
| 2017-05-17 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −25,923 | 118,093 | ||
| 2017-05-16 | Novak Rodger Chief Executive Officer | Exercise or conversion | +24,077 | $1.81 | $44K | 1,239,082 |
| 2017-05-16 | Novak Rodger Chief Executive Officer | Sale | −24,077 | $16.50 | $397K | 1,215,005 |
| 2017-05-16 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −24,077 | 144,016 | ||
| 2017-05-05 | Novak Rodger Chief Executive Officer | Exercise or conversion | +616 | $1.81 | $1K | 1,215,621 |
Page 64 of 74 · 1,471 trades